| Revenue Growth | Clinical up 20.3% sequentially; Logistics down 6.9% sequentially due to seasonality. |
|---|---|
| Mgmt Confidence | Confident in medium-term 30% plus adjusted EBITDA growth including acquisitions. |
| Demand Visibility | Strong new customer pipeline for integrated transplant offering in 2027. |
| Margin Trends | Logistics gross margin rebounded 240bps to 20.8%; Clinical declined 50bps. |
| Op. Leverage | Adjusted SG&A flat over four quarters despite significant organic growth. |
| Pricing Power | Fuel surcharge pass-through revenue impacted logistics margins on owned aircraft. |
| Vol vs Price | Growth driven by market share gains despite 7% industry transplant decline. |
| Segment Growth | Clinical growth led by transplant business; Logistics impacted by shorter distances. |
| New Clients | Gaining market share; strong pipeline for integrated transplant offering mentioned. |
| Capex & Debt | Free cash flow $8.6M; $41.6M cash; $50M share buyback authorized. |
| Regulatory | New OPTN lung allocation rules reduced average flight distances by 10%. |
| Commentary | Focusing on 'integrated organ recovery platform' to drive higher cash conversion. |
| New Launches | Launched local recovery business based on customer demand and surgeon retention. |
Growth
Revenue grew 20.3% sequentially; Clinical segment organic growth exceeded 30% year-over-year.
Outlook
Reiterated 2026 revenue of $285M-$295M and adjusted EBITDA of $33M-$35M.
Risks
Logistics revenue fell 6.9% sequentially; management pivoted on specific Q4 industry volume recovery timing.
The company's earnings call, NASDAQ: SRTA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Strata Critical Medical, Inc.: key numbers
- Share price
- $5.42Close, Nov 16
- Market cap
- $484M
- Shares outstanding
- 89.32MLatest SEC cover page
- Sector
- Energy & Transportation
- Industry
- Transportation ServicesSIC 4700
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Strata Critical Medical, Inc.
All →Strata Critical Medical Q3 2026 Results: Net Loss of $7.62M
Strata Critical Medical, Inc. reported a net loss of $7.6 million for the third quarter of 2026, compared to a net income of $57.4 million in the prior year period, which was significantly bolstered by discontinued operations. Revenue grew to $74.1 million from $49.3 million year-over-year, while the company maintained a cash and cash equivalents balance of $35.1 million as of September 30, 2026.
- Key figure
- Net loss $7.62M
Strata Critical Medical Financial Results
Strata Critical Medical reported Q3 2026 financial results with revenue increasing 50.3% year-over-year to $74.1 million, driven by significant growth in its Clinical segment. The company also announced a new $20 million share repurchase authorization to be executed alongside its ongoing M&A strategy.